soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Semaglutide, a glucagon-like peptide-1 (GLP-1)
Pay in 4 interest-free payments of $6.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 22 - Nov 27
























